Drugs / allogeneic adipose-derived mesenchymal stem cell
allogeneic adipose-derived mesenchymal stem cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04776538 | Feb 2021 → Mar 2024 | — | Rigshospitalet, Denmark | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic adipose-derived mesenchymal stem cell | “Participants will be randomly assigned using block randomisation to one of two parallel groups in a 1:1 ratio to receive ultrasound-guided injection of allogeneic...” PMID 37658468 ↗ Sep 2023 |
| Known as | ASC | “Participants will be randomly assigned using block randomisation to one of two parallel groups in a 1:1 ratio to receive ultrasound-guided injection of allogeneic...” PMID 37658468 ↗ Sep 2023 |
| Known as | ASCs | “This sub study, to the randomised, double-blinded, placebo-controlled trial investigating intraglandular mesenchymal stromal cells for radiation-induced hyposalivation...” PMID 41316394 ↗ Nov 2025 |
| Modality | Cell therapy | “allogeneic adipose-derived mesenchymal stem cell (ASC)” PMID 37658468 ↗ Sep 2023 |
| Route | Other | “intraglandular injections with either ASCs or placebo” PMID 41316394 ↗ Nov 2025 |